Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation

NCT ID: NCT00857948

Last Updated: 2012-03-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 2 single center study designed to compare the safety, local tolerability, and efficacy of 3 strengths of ivermectin treatment conditioner to placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediculus Humanus Capitis (Head Lice)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

head lice Pediculus humanus capitis ivermectin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.15% ivermectin

Participant on 0.15% ivermectin treatment conditioner

Group Type EXPERIMENTAL

ivermectin treatment conditioner

Intervention Type DRUG

Application followed by thorough rinsing of the hair and scalp with water.

0.25% ivermectin

Participants on 0.25% ivermectin treatment conditioner

Group Type EXPERIMENTAL

ivermectin treatment conditioner

Intervention Type DRUG

Application followed by thorough rinsing of the hair and scalp with water.

0.50% ivermectin

Participants on 0.50% ivermectin treatment conditioner

Group Type EXPERIMENTAL

ivermectin treatment conditioner

Intervention Type DRUG

Application followed by thorough rinsing of the hair and scalp with water.

Placebo

participants on Placebo (Vehicle control)

Group Type PLACEBO_COMPARATOR

Placebo, vehicle control

Intervention Type DRUG

Application followed by thorough rinsing of the hair and scalp with water.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ivermectin treatment conditioner

Application followed by thorough rinsing of the hair and scalp with water.

Intervention Type DRUG

Placebo, vehicle control

Application followed by thorough rinsing of the hair and scalp with water.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who are at least 6 months old and weighing at least 15 kg.
* Infestation with head lice and viable nits.
* Are otherwise in a normal state of health.
* Willing and able to attend all study visits as scheduled.
* Agree not to cut or chemically treat their hair in the period between treatment and the final visit.
* The subject and/or his/her parent/legal guardian have provided written informed consent, and, if appropriate, the child has provided assent.
* Females of childbearing potential must have a negative urine pregnancy test at screening and agree to take reasonable precautions against becoming pregnant during the study period.

Exclusion Criteria

* Subjects who have received any over the counter or prescription treatment for head lice in the last 2 weeks.
* Subjects unable to comply with the study obligations and all study visits.
* Subjects with eczema or other chronic conditions of the scalp and skin.
* Subjects in a household with more than 5 infested members.
* Subjects with a history of allergy to ivermectin or any ingredients commonly included in hair products such as shampoos, hair conditioners, or styling aids.
* Subjects with neurologic conditions including a seizure disorder or history of seizures.
* Subjects with an infestation of body lice or pubic lice (determined by questioning).
* Subjects suffering from a condition likely to require medical attention, including administration of oral or systemic antibiotics, oral or systemic corticosteroids, or any other treatment, which in the opinion of the Investigator and visiting physician could influence the results of the study.
* Subjects with other diagnoses which, in the opinion of the Investigator, would interfere with efficacy or safety assessments or would preclude study participation.
* Subjects with very short (shaved) hair.
* Subjects who have been treated with a systemic antibiotic within the previous 2 weeks before screening.
* Subjects who have been previously enrolled in any clinical study within the past 30 days; subjects may not participate in another study while participating in this study.
* Pregnant and/or nursing females.
Minimum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Topaz Pharmaceuticals Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Sanofi Topaz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Global Health Associates of Miami

Miami, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Meinking TL, Mertz-Rivera K, Villar ME, Bell M. Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation. Int J Dermatol. 2013 Jan;52(1):106-12. doi: 10.1111/j.1365-4632.2012.05629.x.

Reference Type DERIVED
PMID: 23278618 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TOP003

Identifier Type: -

Identifier Source: org_study_id